Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$57.50

-3.28 (-5.40%)

07:01
10/12/18
10/12
07:01
10/12/18
07:01

Bristol-Myers reports Phase 3 CheckMate-331 study does not meet primary endpoint

Bristol-Myers Squibb announced topline results from the Phase 3 CheckMate -331 study evaluating Opdivo versus the current standard of care, topotecan or amrubicin, in patients with small cell lung cancer who relapsed following platinum-based chemotherapy. The study did not meet its primary endpoint of overall survival with Opdivo versus chemotherapy. The safety profile of Opdivo in this trial was consistent with that observed in previously reported monotherapy studies involving patients with SCLC. Sabine Maier, M.D., development lead, thoracic cancers, Bristol-Myers Squibb, commented, "Small cell lung cancer is a highly aggressive disease in which significant unmet need remains. We are focused on researching innovative oncology therapies to improve outcomes for patients with lung cancer. We thank the patients, their families, and the physicians involved in the CheckMate -331 study."

  • 17

    Oct

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

BMY Bristol-Myers
$57.50

-3.28 (-5.40%)

10/08/18
GUGG
10/08/18
INITIATION
Target $70
GUGG
Neutral
Bristol-Myers initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started Bristol-Myers with a Neutral rating and $70 price target, contending that near-term Opdivo catalysts are largely in the stock. He sees the risk-reward as being balanced ahead of several trial read outs in 2019 from Bristol and its competitors, Fernandez added.
09/12/18
FBCO
09/12/18
NO CHANGE
FBCO
Neutral
Bristol-Myers' TYK2 efficacy looks better than Otezla, says Credit Suisse
After Bristol-Myers (BMY) presented Phase 2 data for its oral TYK2 inhibitor, BMS-986165, in moderate-to-severe psoriasis at the EAVD meeting, Credit Suisse analyst Vamil Divan said he believes the "robust" data are very encouraging for the ongoing Phase 3 studies. BMS-986165 achieved PASI 75 response rates that are better than what was demonstrated by Celgene's (CELG) Otezla and the safety profile "appears reasonable," Divan tells investors. While BMS-986165 could be highly competitive clinically against other oral treatments, the crowded psoriasis market remains a tough one for new products, added the analyst, who keeps a Neutral rating on Bristol-Myers shares.
09/06/18
MSCO
09/06/18
NO CHANGE
Target $63
MSCO
Equal Weight
Bristol-Myers' TYK2 inhibitor may be underappreciated asset, says Morgan Stanley
Morgan Stanley analyst David Risinger said that Phase 2 data on Bristol-Myers' oral TYK2 inhibitor BMS-986165 will be presented at the EADV meeting on Wednesday September 12, adding that it could be an underappreciated asset if it offers better efficacy than other oral drugs and is safer. To his knowledge, no JAK inhibitors are currently being developed for psoriasis, Risinger noted. The analyst, who said 986165 "theoretically has blockbuster potential," maintains an Equal Weight rating on Bristol shares as further Opdivo lung newsflow is awaited.
08/08/18
08/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dean Foods (DF) upgraded to Hold from Sell at Deutsche Bank. 2. Plantronics (PLT) upgraded to Buy from Neutral at Sidoti with the firm citing attractive valuation. 3. CarGurus (CARG) upgraded to Outperform from Market Perform at JMP Securities and to Outperform from Sector Perform at RBC Capital. 4. Bristol-Myers (BMY) upgraded to Neutral from Underweight at Atlantic Equities. 5. Floor & Decor (FND) upgraded to Buy from Hold at Loop Capital with analyst Anthony Chukumba saying the company continues to post the "best relative performance in the flooring retailing industry." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

HSY

Hershey

$110.01

0.315 (0.29%)

12:09
02/20/19
02/20
12:09
02/20/19
12:09
Hot Stocks
Hershey reaffirms 2019 guidance at CAGNY Conference »

Hershey said that in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

KNX

Knight-Swift

$34.96

0.73 (2.13%)

12:05
02/20/19
02/20
12:05
02/20/19
12:05
Options
Knight Transportation call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

12:05
02/20/19
02/20
12:05
02/20/19
12:05
General news
U.S. corporate bond update: the calendar remains active. »

U.S. corporate bond…

DNLI

Denali Therapeutics

$21.44

-0.16 (-0.74%)

12:03
02/20/19
02/20
12:03
02/20/19
12:03
Hot Stocks
Denali granted orphan status for mucopolysaccharidosis treatment »

The FDA granted Denali…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDY

Dr. Reddy's

$35.97

-0.45 (-1.24%)

12:03
02/20/19
02/20
12:03
02/20/19
12:03
Hot Stocks
Dr. Reddy's announces re-launch of buprenorphine, naloxone sublingual film »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

HSY

Hershey

$109.86

0.165 (0.15%)

12:01
02/20/19
02/20
12:01
02/20/19
12:01
Earnings
Hershey backs FY19 adjusted EPS growth view of 5%-7%, consensus $5.64 »

Backs FY19 net sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

QTT

Qutoutiao

$12.66

0.25 (2.01%)

12:01
02/20/19
02/20
12:01
02/20/19
12:01
Downgrade
Qutoutiao rating change  »

Qutoutiao downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

BHC

Bausch Health

$23.23

-1.94 (-7.71%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Bausch Health falls -7.7% »

Bausch Health is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 12

    Mar

IDT

IDT Corp

$6.48

-0.68 (-9.50%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
IDT Corp falls -9.1% »

IDT Corp is down -9.1%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMI

Owens & Minor

$6.62

-1.32 (-16.62%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Owens & Minor falls -16.6% »

Owens & Minor is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

I

Intelsat

$24.38

2.755 (12.74%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Intelsat rises 12.8% »

Intelsat is up 12.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 11

    Mar

  • 11

    Mar

QUAD

Quad/Graphics

$16.58

2.04 (14.03%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Quad/Graphics rises 14.4% »

Quad/Graphics is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

LKSD

LSC Communications

$9.47

1.18 (14.23%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
LSC Communications rises 14.6% »

LSC Communications is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLNE

Clean Energy

$2.23

0.24 (12.06%)

11:58
02/20/19
02/20
11:58
02/20/19
11:58
Hot Stocks
Clean Energy jumps 12% after seeing demand increases for RNG from refuse sector »

Clean Energy Fuels,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Mar

  • 12

    Mar

TKC

Turkcell

$6.97

0.06 (0.87%)

11:56
02/20/19
02/20
11:56
02/20/19
11:56
Hot Stocks
Breaking Hot Stocks news story on Turkcell 

Turkcell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 19

    Mar

DDAIF

Daimler AG

$0.00

(0.00%)

11:48
02/20/19
02/20
11:48
02/20/19
11:48
Periodicals
German prosecutors launch new probe into Daimler, Reuters reports »

Prosecutors in Germany…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

IQ

iQIYI

$22.76

0.43 (1.93%)

11:45
02/20/19
02/20
11:45
02/20/19
11:45
Options
iQiyi call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 20

    Mar

11:45
02/20/19
02/20
11:45
02/20/19
11:45
General news
Treasury's $18 B 2-year FRN reopening was a little soft »

Treasury's $18 B…

11:41
02/20/19
02/20
11:41
02/20/19
11:41
Conference/Events
UBS services analyst to hold an analyst/industry conference call »

Services Analyst Geiger,…

DVN

Devon Energy

$31.18

2.87 (10.14%)

11:41
02/20/19
02/20
11:41
02/20/19
11:41
Hot Stocks
Devon Energy sees FY19 total production 294-309 MBoe/d »

Sees FY19 oil production…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 27

    Feb

  • 28

    Feb

  • 22

    May

WIX

Wix.com

$110.04

-15.66 (-12.46%)

11:38
02/20/19
02/20
11:38
02/20/19
11:38
Recommendations
Wix.com analyst commentary  »

Wix.com strategy change…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 18

    Mar

11:35
02/20/19
02/20
11:35
02/20/19
11:35
General news
2-Yr FRN Note Auction Bid/Cover data reported »

2-Yr FRN Note Auction…

11:35
02/20/19
02/20
11:35
02/20/19
11:35
General news
2-Yr FRN Note Auction Total Amount data reported »

2-Yr FRN Note Auction…

DATA

Tableau

$128.02

1.08 (0.85%)

11:30
02/20/19
02/20
11:30
02/20/19
11:30
Options
Size time spread in Tableau Software paints a bullish picture »

Size time spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 06

    Mar

  • 07

    Mar

MO

Altria Group

$50.35

1.41 (2.88%)

11:26
02/20/19
02/20
11:26
02/20/19
11:26
Hot Stocks
Altria Group backs long-term adjusted EPS growth at 7%-9% annual rate »

In comments being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.